Loading stock data…
$1.51+0.01 (+0.67%)
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
MediciNova, Inc. in the Healthcare sector is trading at $1.51 with a market capitalization of $88M. Wall Street consensus targets $8.25 (4 analysts), implying a +446.4% move over the next 12 months. The stock is currently near its 52-week low of $1.17, remaining 0.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $458,439↑ | $186,984↑ | $151,739↑ | $123,319↓ | $134,599 |
| Gross Profit | $317,759↑ | $16,883↑ | $4,754↓ | $8,047↓ | $18,250 |
| Operating Income | -$2.54M↑ | -$2.84M↑ | -$3.09M↑ | -$3.38M↑ | -$3.61M |
| Net Income | -$2.31M↑ | -$2.59M↑ | -$2.80M↑ | -$3.05M↑ | -$3.28M |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory ...